SUPN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SUPN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-13), Supernus Pharmaceuticals's current share price is $28.96. Supernus Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $10.11. Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 2.86.
The historical rank and industry rank for Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, Supernus Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 24.68. The lowest was 2.42. And the median was 5.03.
SUPN's Cyclically Adjusted PB Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Supernus Pharmaceuticals's adjusted book value per share data for the three months ended in Dec. 2023 was $16.840. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $10.11 for the trailing ten years ended in Dec. 2023.
The historical data trend for Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 4.31 | 4.12 | 3.25 | 2.83 | 2.86 |
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 28.96 | / | 10.11 | |
= | 2.86 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Supernus Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:
Adj_Book | = | Book Value per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 16.84 | / | 129.4194 | * | 129.4194 | |
= | 16.840 |
Current CPI (Dec. 2023) = 129.4194.
Supernus Pharmaceuticals Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201403 | 0.690 | 99.695 | 0.896 |
201406 | 0.792 | 100.560 | 1.019 |
201409 | 1.540 | 100.428 | 1.985 |
201412 | 0.947 | 99.070 | 1.237 |
201503 | 1.991 | 99.621 | 2.587 |
201506 | 2.113 | 100.684 | 2.716 |
201509 | 2.248 | 100.392 | 2.898 |
201512 | 1.796 | 99.792 | 2.329 |
201603 | 2.593 | 100.470 | 3.340 |
201606 | 2.848 | 101.688 | 3.625 |
201609 | 3.500 | 101.861 | 4.447 |
201612 | 3.837 | 101.863 | 4.875 |
201703 | 4.103 | 102.862 | 5.162 |
201706 | 4.522 | 103.349 | 5.663 |
201709 | 4.909 | 104.136 | 6.101 |
201712 | 5.213 | 104.011 | 6.486 |
201803 | 6.815 | 105.290 | 8.377 |
201806 | 7.484 | 106.317 | 9.110 |
201809 | 8.074 | 106.507 | 9.811 |
201812 | 8.659 | 105.998 | 10.572 |
201903 | 9.165 | 107.251 | 11.059 |
201906 | 9.970 | 108.070 | 11.940 |
201909 | 10.622 | 108.329 | 12.690 |
201912 | 11.334 | 108.420 | 13.529 |
202003 | 11.675 | 108.902 | 13.875 |
202006 | 12.655 | 108.767 | 15.058 |
202009 | 13.459 | 109.815 | 15.862 |
202012 | 14.089 | 109.897 | 16.592 |
202103 | 14.236 | 111.754 | 16.486 |
202106 | 14.782 | 114.631 | 16.689 |
202109 | 15.240 | 115.734 | 17.042 |
202112 | 15.319 | 117.630 | 16.854 |
202203 | 15.518 | 121.301 | 16.557 |
202206 | 15.730 | 125.017 | 16.284 |
202209 | 15.777 | 125.227 | 16.305 |
202212 | 16.334 | 125.222 | 16.882 |
202303 | 16.746 | 127.348 | 17.018 |
202306 | 16.850 | 128.729 | 16.940 |
202309 | 16.697 | 129.860 | 16.640 |
202312 | 16.840 | 129.419 | 16.840 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Tami Tillotson Martin | officer: Sr. V.P., Regulatory Affairs | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Newhall Charles W Iii | director | 1119 ST PAUL ST, BALTIMORE MD 21202 |
Frederick M. Hudson | director | 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Frank Mottola | officer: Sr VP, Quality, GMP Oper. & IT | 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Bethany Sensenig | director | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Jack A. Khattar | director, officer: President, CEO | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Padmanabh P. Bhatt | officer: Sr. VP of IP, CSO | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Timothy C Dec | officer: Senior Vice-President & CFO | C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878 |
Jonathan Rubin | officer: SVP, Chief Medical Officer | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Schwabe Stefan K.f. | officer: Executive Vice President R&D | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Gregory S Patrick | officer: VP, Chief Financial Officer | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
James Patrick Kelly | officer: Executive Vice-President & CFO | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Carrolee Barlow | director | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Victor Vaughn | officer: Sr. VP of Sales | C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850 |
M James Barrett | director, 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
From GuruFocus
By sperokesalga sperokesalga • 02-10-2023
By sperokesalga sperokesalga • 02-14-2023
By Marketwired • 10-16-2023
By GlobeNewswire • 10-16-2023
By sperokesalga sperokesalga • 03-01-2023
By Value_Insider Value_Insider • 11-22-2022
By GlobeNewswire GlobeNewswire • 11-22-2022
By Value_Insider Value_Insider • 11-08-2022
By sperokesalga sperokesalga • 04-25-2023
By sperokesalga sperokesalga • 05-31-2023